Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings

Key Points

• Aura Biosciences shares fell sharply after the company reported a second-quarter loss of $0.48 per share, missing the $0.38-per-share consensus estimate by $0.10.
• The company is refocusing research and development on eye cancer while reportedly eliminating about 20% of its workforce and restructuring its executive team, highlighting efforts to cut costs amid ongoing losses.
• Analysts remain mixed but see potential upside: the consensus price target is $17.50, while HC Wainwright maintained a Buy rating with an $18 target despite lowering it from $24.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $8.04, but opened at $7.77. Aura Biosciences shares last traded at $7.45, with a volume of 112,681 shares changing hands.

The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.10).

Aura Biosciences News Summary

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and an $18 price target. Although the target was reduced from $24, it remains substantially above the stock’s recent $7.39 level, signaling that the analyst sees significant potential upside. HC Wainwright projects 2027 quarterly losses of $0.40 to $0.42 per share. StreetInsider analyst report
• Neutral Sentiment: The company is refocusing research and development on eye cancer. The strategic shift could concentrate resources on Aura’s core pipeline, but near-term execution and funding risks remain as the company continues to operate at a loss. Fierce Biotech workforce and management changes article
• Neutral Sentiment: Reported short-interest data provides no useful trading signal. The reported short interest was zero, with a zero days-to-cover ratio; the data also showed an invalid percentage change, suggesting the figures may be incomplete or unreliable.
• Negative Sentiment: Aura reported a second-quarter 2026 loss of $0.48 per share, missing the consensus estimate of a $0.38 loss. The $0.10-per-share shortfall reinforces concerns about operating expenses and the company’s path toward profitability. Analysts expect a full-year loss of approximately $1.73 per share. Aura Biosciences second-quarter 2026 results
• Negative Sentiment: Aura is reportedly eliminating about 20% of its workforce and changing its executive structure. While the cuts may reduce costs, investors may interpret them as evidence of financial pressure or delays in the development strategy.

Analysts Set New Price Targets

AURA has been the subject of several recent research reports. Leerink Partners set a $17.00 price objective on Aura Biosciences in a research note on Tuesday, May 12th. Wall Street Zen upgraded shares of Aura Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings raised shares of Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 14th. Finally, HC Wainwright lowered their price target on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $17.50.

Insider Activity at Aura Biosciences

In other news, insider Anthony S. Gibney sold 12,824 shares of the firm's stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the sale, the insider owned 265,354 shares of the company's stock, valued at approximately $1,703,572.68. This trade represents a 4.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.90% of the company's stock.

Institutional Trading of Aura Biosciences

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Aura Biosciences during the 2nd quarter worth $33,424,000. Nantahala Capital Management LLC grew its holdings in shares of Aura Biosciences by 67.1% during the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock worth $13,257,000 after purchasing an additional 850,000 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Aura Biosciences by 233.3% during the fourth quarter. Millennium Management LLC now owns 617,338 shares of the company's stock worth $3,364,000 after purchasing an additional 432,117 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Aura Biosciences by 16.7% during the third quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company's stock worth $17,863,000 after purchasing an additional 413,001 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Aura Biosciences in the 2nd quarter valued at about $842,000. Hedge funds and other institutional investors own 96.75% of the company's stock.

Aura Biosciences Trading Down 9.7%

The firm has a market capitalization of $751.28 million, a PE ratio of -4.18 and a beta of 0.40. The company has a fifty day moving average price of $6.96 and a two-hundred day moving average price of $6.71.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source